Leigh syndrome, a rare genetic disorder, poses significant challenges for families, often leading to devastating outcomes as it progressively depletes energy from the brain and muscles. Currently, there is no cure, and affected children frequently face a grim prognosis, with many not surviving beyond a few years post-diagnosis.
In a groundbreaking study, researchers have identified sildenafil, the active component of Viagra, as a potential treatment for this condition. By screening thousands of existing medications using patient-derived cells, they discovered that sildenafil not only improved various disease-related parameters in laboratory settings but also yielded promising results in animal models. Six patients treated off-label exhibited noteworthy clinical improvements, although further validation through rigorous clinical trials is essential.
A Surprising Discovery
Leigh syndrome occurs in approximately one in 36,000 to 40,000 births, primarily targeting the mitochondria, which are essential for energy production in cells. When these organelles malfunction, energy-dependent tissues, particularly in the brain and muscles, are severely affected, leading to symptoms such as seizures and developmental delays.
Addressing the treatment of this rare condition is complicated by the challenges of conducting large clinical trials and the difficulty of obtaining living brain tissue from affected children for research. To navigate these obstacles, an international team of researchers innovatively transformed skin cells from Leigh syndrome patients into stem cells, subsequently developing them into neurons that replicated the metabolic defects characteristic of the disorder.
With this model in place, the team screened over 5,500 approved drugs to identify candidates capable of restoring cellular energy balance. Dr. Ole Pless, a lead author from the Fraunhofer Institute for Translational Medicine and Pharmacology, noted that this represents the most extensive drug screening conducted for Leigh syndrome to date.
Sildenafil emerged as a standout candidate due to its ability to inhibit the enzyme PDE5. While commonly known for its use in treating erectile dysfunction in adults, sildenafil is also safely administered to infants with pulmonary hypertension, highlighting its established safety profile.
Promising Results in Animal Models
Following laboratory success, the researchers advanced to testing sildenafil in animal models, including mice and pigs genetically predisposed to Leigh syndrome. The results were encouraging; sildenafil not only extended the lifespan of mice but also significantly improved muscle strength. One treated pig demonstrated remarkable stability for over six months, a significant deviation from the typical rapid decline associated with the disease.
Vivian Gama, a cell biologist at Vanderbilt University, expressed her enthusiasm for the study, stating that sildenafil could be a "really promising compound" for combating this challenging childhood illness.
Encouraged by these findings, physicians initiated off-label treatments for six Leigh syndrome patients, aged between nine months and 38 years. Remarkably, patients experienced substantial improvements in muscle strength and a reduction in neurological symptoms, with one child increasing their walking distance tenfold.
The Path Forward
While the initial results are promising, caution is advised. Leigh syndrome's unpredictable nature complicates the assessment of treatment efficacy. The research team is aware of these challenges and has received orphan-drug designation in Europe for sildenafil's use in Leigh syndrome, facilitating future clinical trials.
As the scientific community prepares for larger, controlled studies, the potential of sildenafil as a treatment for Leigh syndrome holds promise, paving the way for advancements in addressing rare genetic disorders and improving the quality of life for affected families.